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Available online 5 June 2016Background: It is an unresolved issue why some kidney transplant recipients with pretransplant donor-speciﬁc
HLA antibodies (DSA) show a high transplant failure rate, whereas in other patients DSA do not harm the
graft. We investigated whether help from preactivated T-cells might be necessary for DSA to exert a deleterious
effect.
Methods: The impact of pretransplant DSA and immune activation marker soluble CD30 (sCD30) on 3-year graft
survival was analyzed in 385 presensitized kidney transplant recipients.
Findings: A deleterious inﬂuence of pretransplant DSA on graft survival was evident only in patients who were
positive for the immune activation marker sCD30. In the absence of sCD30 positivity, 3-year graft survival was
virtually identical in patients with or without DSA (83.1 ± 3.9% and 84.3 ± 2.8%, P= 0.81). A strikingly lower
3-year graft survival rate of 62.1 ± 6.4% was observed in patients who were both sCD30 and DSA positive (HR
2.92, P b 0.001). Even in the presence of strong DSA with ≥5000 MFI, the 3-year graft survival rate was high if
the recipients were sCD30 negative.
Interpretation: Pretransplant DSA have a signiﬁcantly deleterious impact on graft survival only in the presence of
high pretransplant levels of the activation marker sCD30.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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367C. Süsal et al. / EBioMedicine 9 (2016) 366–3711. IntroductionKidney transplants involving recipientswhopossess lymphocytotoxic
antibodies againstmismatchedHLA antigens of the donor are at high risk
of antibody-mediated rejection. In today's clinical practice such trans-
plants are generally avoided (Tait et al., 2013). A complement-dependent
cytotoxicity (CDC) crossmatch that detects donor-directed antibodies in
the patient's sera was introduced in the 1970's and, supplemented by
the ﬂow cytometry version, allows the exclusion of unfavorable recipient
donor combinations (Patel and Terasaki, 1969). The CDC technique has
the drawback of not being highly sensitive and has been criticized for
not detecting all clinically relevant antibodies. During recent years,
more sensitive solid-phase assays based on ELISA, ﬂow cytometry and
Luminex® platforms were introduced for detection and speciﬁcation of
donor-speciﬁc HLA antibodies (DSA), and the pretransplant inclusion of
HLA antibody speciﬁcities in the recipient's waiting list proﬁle for
allowing exclusion of ‘unacceptable HLA antigen mismatches' in the
‘virtual crossmatch’ has become routine practice (Tait et al., 2013). Of
modern antibody assays, the Luminex® single antigen bead (SAB) tech-
nique has, despite the drawback that it occasionally gives false positive
results due to the presence of denaturedHLA on the bead surface (Cai et
al., 2009), the highest sensitivity and resolution and is therefore used
widely.
Contradictory results were obtained with respect to whether all
pretransplant DSA detected by the sensitive SAB technique are deleteri-
ous (van den Berg-Loonen et al., 2008; Eng et al., 2008). In a retrospec-
tive study, we found that the incidence of pretransplant DSA was not
higher in kidney recipients with graft loss than in recipients with func-
tioning grafts if the antibodieswere reactive exclusively in the SAB assay
but not in the less sensitive CDC or ELISA assays (Susal et al., 2011).
While the antibodies often seemed to act as mediators of allograft de-
struction, we and others noticed that, in some recipients, antibodies
persisted but did no harm to the graft or disappeared (Susal et al.,
2015; Knight et al., 2013).
The complement (C)-activating capacity of DSA, indirectly assessed
by classical pathway component C1q binding, was proposed as a dis-
criminator between deleterious and non-harmful antibodies (Chen et
al., 2011; Loupy et al., 2013). However, in today's practicemost patients
with pretransplant C1q-binding DSA are excluded from transplantation
because these antibodies, if sufﬁciently strong, react positively in the
CDC crossmatch. In retrospective testing, pretransplant C1q-binding
DSAwere therefore rare in patients who received a transplant after rou-
tine crossmatching (Otten et al., 2012). Even if detected pretransplant,
they often disappeared after transplantation without inﬂicting harm
(Schaefer et al., 2016). In a small cohort of six patients with graft loss
due to antibody-mediated rejection, we obtained preliminary evidence
that the deleterious effect of pretransplant DSA might be related to T-
cell help originating from a preactivated immune system (Schaefer et
al., 2016). T-cell support is required for the switch of B cells to plasma
cells that produce antibodies with high afﬁnity for mismatched donor
HLA. Previous data showed that increased levels of the immune system
activation marker soluble CD30 (sCD30) are associated with an in-
creased risk of graft loss (Susal et al., 2002; Heinemann et al., 2007;
Saini et al., 2008).
Because of our previous failure to ﬁnd an association of graft failure
with pretransplant DSA that exclusively reacted in the exquisitely sensi-
tive SAB assay (Susal et al., 2011), we focused in the present study on
pretransplant sera containing CDC- or ELISA-reactive antibodies, select-
ed without regard to donor-speciﬁcity. Antibodies detected with these
assays of lower sensitivity have been found in the past to correlate
with kidney graft outcome (Schonemann et al., 1998; Susal and Opelz,
2002). In patients possessing such antibodies, we analyzed whether
pretransplant HLA antibodies with donor speciﬁcity, as identiﬁed in
the highly sensitive SAB assay, might require a preactivated immune
system, as indicated by high serum sCD30 at the time of transplantation,
as a prerequisite for unfolding a deleterious action.2. Methods
2.1. Patients
Adult (≥18 years old) recipients of deceased donor kidney trans-
plantswhowere transplanted 1996–2011were studied retrospectively.
Patients with multi-organ transplants were excluded. We selected all
385 patients from the Collaborative Transplant Study (CTS) combined
serum and DNA study (www.ctstransplant.org) whose last
pretransplant serum was reported by the participating centers to be
positive in the CDC panel reactivity assay (PRA) or who tested positive
in the CTS serum study for ELISA-reactive HLA antibodies (AbScreen,
Biorad, Dreieich, Germany). These patientswere termed “presensitized”
and their frozen-stored serum and DNA specimen were used for addi-
tional testing. Based on previous ﬁndings, an optical density (OD) of
≥0.300 in ELISA and N0% reactivity in the CDC-PRA assay were used as
cut-offs for positivity (Susal and Opelz, 2002). Thirteen transplant cen-
ters participated both in the serum and the DNA study, and transplants
from these centerswere selected for the current project. The availability
of DNA on recipients and their respective donors allowed for the retro-
spective typing of HLA A, B, C, DRB1, DRB3, DRB4, DRB5, DQA1, DQB1,
and DPB1 antigens, and thereby the precise deﬁnition of DSA. Patient
consent and ethics committee approvalwas obtained and the investiga-
tions were performed in accordance with the Declaration of Helsinki.
Demographic characteristics of the patients are shown in Table 1. Only
11 (3%) of the patients had an incomplete 3 year follow-up. Character-
istics of patients subdivided into further subgroups according to
sCD30 positivity or negativity are shown in Supplementary Table S1.
2.2. Measurements
The sera of the 385 presensitized patients were tested in the Heidel-
berg laboratory for serum sCD30 content using the ELISA kit of
eBioscience (San Diego, USA) and for HLA antibodies using the
LABScreen kits of One Lambda (Canoga Park, CA) which utilize single
HLA antigen-coated beads and enable the identiﬁcation of IgG alloanti-
body speciﬁcities against HLA A, B, C, DRB1, DRB3, DRB4, DRB5, DQA1,
DQB1, and DPB1. No clinical cut-off for these assays is recommended
by the provider companies. The receiver operating characteristic curve
analysis, in which 3-year graft as well as death-censored graft survival
was analyzed at ﬁve different cut-offs (70, 80, 90, 100, 110 ng/ml), indi-
cated 80 ng/ml as the most suitable cut-off for sCD30 testing. Based on
experience from previous studies (Susal et al., 2011), a mean ﬂuores-
cence intensity (MFI) of ≥1000, was considered positive for HLA anti-
body reactivity. For high resolution typing of HLA A, B, C, DRB1, DQA1,
and DQB1 antigens at the allele level, CTS PCR-SSP Tray and CTS-Se-
quence Kits (Heidelberg, Germany), and for HLA DRB3, DRB4, DRB5
and DPB1 typing Olerup SSP kits (Saltsjöbaden, Sweden) were used.
All DSA positive sera were analyzed for the presence of C1q-binding an-
tibodies using the C1qScreenTM kit of One Lambda and applying a cut-
off of 300 MFI (Chen et al., 2011).
2.3. Statistical analysis
Graft as well as death-censored graft survival rates were computed
according to the Kaplan-Meier method and are expressed as % ± stan-
dard error. Log-rank test, Fisher's exact test, Mann-Whitney U test and
multivariable Cox regression were used for statistical analysis. In multi-
variable analysis, geographic region, year and number of transplant, re-
cipient and donor gender and age, original disease causing end stage
renal failure, pretransplant clinical evaluation of the patient, HLA-
A + B + DR mismatches, pretransplant time on dialysis, and inten-
tion-to-treat immunosuppressive therapy (antibody induction, calcine-
urin inhibitors, anti-proliferatives) were considered as confounders.
Patients negative in sCD30 and DSA testing served as reference group
for the calculation of hazard ratios. P values below 0.05were considered
Table 1
Demographics of study patients⁎.
Characteristic
Without DSA
n = 231
With DSA
n = 154
Total
n = 385
Geographical region
Europe
North America
175 (76%)
56 (24%)
138 (90%)
16 (10%)
313 (81%)
72 (19%)
Transplant year
1996–2001
2002–2006
2007–2011
39 (17%)
88 (38%)
104 (45%)
25 (16%)
61 (40%)
68 (44%)
64 (17%)
149 (39%)
172 (45%)
Transplant number
First transplant
Retransplant
159 (69%)
72 (31%)
67 (44%)
87 (56%)
226 (59%)
159 (41%)
Recipient sex
Female
Male
104 (45%)
127 (55%)
90 (58%)
64 (42%)
194 (50%)
191 (50%)
Recipient racea
Caucasian
Other
203 (99%)
3 (1%)
135 (98%)
3 (2%)
338 (98%)
6 (2%)
Recipient age (years)
Mean ± SD 49.3 ± 13.0 49.7 ± 12.1 49.4 ± 12.6
Donor age (years)
Mean ± SD 47.6 ± 16.7 47.2 ± 17.5 47.5 ± 17.0
HLA-A + B + DR mismatches
0–1
2–4
5–6
65 (28%)
146 (63%)
20 (9%)
23 (15%)
112 (73%)
19 (12%)
88 (23%)
258 (67%)
39 (10%)
Initial immunosuppressionb
CNI
Mycophenolates
Steroids
221 (97%)
210 (92%)
220 (96%)
143 (94%)
144 (95%)
150 (99%)
364 (96%)
354 (93%)
370 (97%)
Antibody induction therapyb
ATG
IL2-RA
Other
None
16 (7%)
85 (37%)
4 (2%)
123 (54%)
27 (18%)
45 (30%)
1 (1%)
79 (52%)
43 (11%)
130 (34%)
5 (1%)
202 (53%)
IgG-anti-HLA antibodies
Class I positive
Class II positive
89 (39%)
69 (30%)
96 (62%)
98 (64%)
185 (48%)
167 (43%)
Soluble CD30 (ng/ml)
b 80
≥ 80
174 (75%)
57 (25%)
96 (62%)
58 (38%)
270 (70%)
115 (30%)
3-year follow-up
Complete
Incomplete
224 (97%)
7 (3%)
150 (97%)
4 (3%)
374 (97%)
11 (3%)
SD, standard deviation; CNI, calcineurin inhibitors; ATG, antithymocyte globulin; IL2-RA,
interleukin-2 receptor antagonist.
⁎ There are signiﬁcant differences between patients with and without DSA in geo-
graphical region (P b 0.001), transplant number (P b 0.001), recipient sex (P = 0.012),
HLA-A + B + DR mismatches (P = 0.007), antibody induction therapy (P = 0.008),
IgG-anti-HLA antibodies (P b 0.001) and soluble CD30 (P= 0.006).
a Data on race are not collected at transplant centers in some European countries due to
legal restriction.
b Immunosuppressivemedication of three patients without DSA and two patients with
DSA was unknown.
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sion 22.0 (SPSS Inc., IBM Corporation, Somers, NY, USA) was used.
2.4. Role of the funding source
No outside funding was obtained for this study.
3. Results
115 of the 385 (30%) presensitized patients had a pretransplant
sCD30 serum content of ≥80 ng/ml and were termed sCD30 positive.
The 3-year graft survival rate in these 115 recipients was 73.8 ± 4.1%,
signiﬁcantly lower than the 83.8±2.3% rate in the remaining 270 recip-
ients who were presensitized but sCD30 negative (log rank P=0.022).
All 385 presensitized patients as determined by CDC or ELISA testing
also were positive for HLA antibodies in the highly sensitive SAB assay,
and 154 of the 385 (40%) possessed SAB-detected antibodies speciﬁcagainst mismatched donor HLA (=donor-speciﬁc antibodies, DSA).
The 3-year graft survival in these 154 DSA positive patients was
75.1 ± 3.5%, signiﬁcantly lower than the 84.7± 2.4% rate in the 231 pa-
tients who had antibodies that were not directed against donor HLA
(P= 0.017, data not shown).
Our further analysis focused on the154 patientswhopossessed SAB-
detected pretransplant DSA. As shown in Fig. 1, a deleterious inﬂuence
of pretransplant DSA on graft survival was evident only in patients
who were positive pretransplant for the immune activation marker
sCD30. In sCD30 negative patients, 3-year graft survival was nearly
identical in patients regardless of the DSA status (sCD30 negative,
with DSA: 83.1 ± 3.9% versus sCD30 negative, without DSA: 84.3 ±
2.8%, P= 0.81, Fig. 1a). Of all possible combinations of sCD30 and DSA
status, the lowest 3-year graft survival was found in the sCD30 positive,
with DSA cohort (62.1 ± 6.4%) (Fig. 1b) and was signiﬁcantly lower
than in all the other groups (sCD30 positive, with DSA P = 0.003,
sCD30 negative, with DSA P = 0.003, sCD30 negative, without DSA
P b 0.001). If the recipients were sCD30 negative, even in the presence
of strong DSA reactingwithMFI of ≥5000 (n= 55) the 3-year graft sur-
vival rate was a high 92.6 ± 3.6%, not inferior to the 84.3 ± 2.8% rate in
the 174 patients without DSA (P= 0.13, data not shown).
When patients who died with a functioning graft were censored,
death-censored graft survival rates were equivalent in DSA positive
and DSA negative presensitized patients if they were negative for the
immune activation marker sCD30 (sCD30 negative, DSA positive vs.
sCD30 negative, DSA negative; 86.8±3.6% vs. 89.9±2.3%, respectively,
P = 0.50, Supplementary Fig. S1a). Only if sCD30 was positive, death
censored graft survival was signiﬁcantly lower in 58 patients who
were positive for DSA (74.8 ± 5.9%) than in the 57 presensitized pa-
tients who were DSA negative (89.2 ± 4.2%, P= 0.036, Supplementary
Fig. S1b). In sCD30 positive patients DSA positivity had a signiﬁcant im-
pact also on patient survival (with DSA 83.3 ± 5.1% vs. without DSA:
96.5 ± 2.4%, P= 0.020; Supplementary Fig. S2b).
Supportive data were obtained when class I or class II DSA positive
patients were analyzed separately (Fig. 2). Graft survival was low in
class I or class II DSA positive patients who were sCD30 positive (class
I DSA: 61.2 ± 7.0%; class II DSA: 60.0 ± 8.9%), signiﬁcantly inferior to
the respective 78.2 ± 5.2% and 91.7 ± 4.0% rates in class I or class II
DSA positive patients who were sCD30 negative: P = 0.039 and
P b 0.001, respectively). Even in the co-presence of class I and class II
DSA, sCD30 negative patients (n= 18) showed a good 3-year graft sur-
vival rate of 88.9 ± 7.4%, as compared to 57.1 ± 10.8% in 21 sCD30 pos-
itive patientswith class I and class II DSA (P=0.029, Supplementary Fig.
S3).
Cox multivariable analysis considering the confounders listed under
‘Methods’ conﬁrmed that the risk of graft loss during the ﬁrst
3 posttransplant years was not increased in DSA positive patients if
they were negative for sCD30 (HR 1.16, 95% CI 0.62–2.19; P = 0.64).
In contrast, patients positive for DSA as well as sCD30 showed a 2.92
times increased risk of graft loss (HR 2.92, 95% CI 1.60–5.33;
P b 0.001). The risk was not increased in presensitized patients who
were positive only for sCD30 and DSA negative (HR 0.98, 95% CI 0.44–
2.21; P= 0.97).
4. Discussion
This analysis was based on a retrospective study of presensitized pa-
tients transplanted between 1996 and 2011, which has the advantage
that it was unknown at the time of transplantationwhether the patients
possessed DSA or not and the recipients were therefore not subjected to
special antibody removal desensitization protocols. Because frozen
pretransplant patient sera as well as patient and donor DNA samples
were available, high resolution HLA typing, high sensitivity SAB anti-
body speciﬁcation, as well as serum sCD30 testing could be carried out
retrospectively on transplants with already known clinical outcome.
Our key ﬁnding was that pretransplant DSA had a deleterious impact
Fig. 1. Impact of pretransplant DSA on graft survival. Patients with andwithout DSA show similar survival rates in the absence of high pretransplant sCD30 (a). In contrast, graft survival is
signiﬁcantly impaired in DSA positive patients if they simultaneously have high pretransplant sCD30 (b).
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of the immune activation marker sCD30.
In spite of improvements in kidney graft survival during the last de-
cades, recipients with preformed DSA against donor HLA continue to be
at high risk of rejection.Waiting-list patients with broadly-reactive HLA
antibodies, by deﬁnition, possess DSA against many potential donors
and, as a consequence, often experience prolonged waiting times for a
deceased donor kidney. Not uncommonly such patients die on the
waiting list before they can be transplanted. Live donor transplantation
is often denied if potential recipients possess DSA. Some transplant
centers perform transplantations after the elimination of DSA by plasma
exchange or immunoadsorption, combined with potent immunosup-
pression which often includes the B- and T-cell-eliminating agents ri-
tuximab and ATG, with variable success (Morath et al., 2010; Vo et al.,
2015). Interestingly, however, experience has shown that even withoutFig. 2. Impact of pretransplant sCD30 on graft survivspecial treatment measures, certain patients who possess DSA do well
with their transplant (van den Berg-Loonen et al., 2008; Knight et al.,
2013; Loupy et al., 2013; Schaefer et al., 2016). These patients should
not be exposed unnecessarily to the deleterious side effects of intensi-
ﬁed treatment or excluded from transplantation altogether. The prac-
tice of enrolling all patients with pretransplant DSA in intensiﬁed
treatment protocols is defensible only in the absence of a diagnostic
tool that allows the differentiation of harmful from non-harmful DSA.
Data obtained in the present study indicate that pretransplant determi-
nation of the activation marker sCD30 (Susal et al., 2002; Saini et al.,
2008) is a diagnostic tool which can differentiate between patients
with harmful and harmless DSA.
Perhaps the most important aspect of the current ﬁndings is that
only 38% of the DSA positive patients were sCD30 positive and thereby
identiﬁed as truly high risks. As many as 62% of DSA positive patientsal in patients with class I (a) or class II DSA (b).
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were not necessary. This applied to patients with DSA against HLA
class I, class II, or both, and irrespective of whether the DSAwere strong,
as indicated by highMFI.We and others have shown previously that the
C1q-binding capacity of DSA can serve as a discriminator between del-
eterious and non-harmful HLA antibodies that appear in the recipient's
serum after transplantation (Susal et al., 2015; Loupy et al., 2013; Yabu
et al., 2011). In clinical practice, only few patients who possess C1q-
binding DSA prior to transplantation are transplanted due to antibody
reactivity in the CDC crossmatch. This is a logical explanationwhy an as-
sociation of C1q-binding DSAwith graft failure could not be established
in studies of pretransplant sera (Loupy et al., 2013; Otten et al., 2012). In
the present study, pretransplant C1q-bindingDSAwere detected in only
5 of the 58 sCD30 and DSA positive high-risk patients, an insufﬁcient
number for statistically meaningful analysis. Another relevant observa-
tion is that, in previous studies, many patients with pretransplant C1q-
reactive antibodies appeared to lose their antibody reactivity
posttransplant with no apparent deleterious effect on the graft (Susal
et al., 2015; Schaefer et al., 2016). In the current study, pretransplant
DSA positive, sCD30 negative patients showed virtually identical graft
survival rates as DSA negative patients. One would have thought that
the presence of DSA at the time of transplantation would be harmful
to the graft in any case, if not via complement-activation then through
antibody-dependent cytotoxicity which can inﬂict tissue damage by ac-
tivating macrophages and natural killer cells. Such was not the case.
Elevated sCD30 may indicate an increased immunological capacity
to react against foreign HLA antigens. Due to contact with
bioincompatible dialysis membranes and exposure to HLA or HLA-
cross-reactive infectious agents (D'Orsogna et al., 2011), end-stage
renal disease patients exhibit alterations in their immune response, in-
cluding increased numbers of interferon (INF)-γ-producing HLA-cross-
reactive memory T-cells, reduced numbers of regulatory T-cells, aug-
mented in vitro expansion of T-cells expressing CD30, and an increased
serum sCD30 content (Susal et al., 2002; Velásquez et al., 2012). Our
group reported that cytomegalovirus infection can lead to an increase
of serum sCD30 levels in transplant patients (Weimer et al., 2006).
Chan et al. identiﬁed CD30+ T-cells as the major INF-γ and IL-5 cyto-
kine-producing human T-lymphocyte subset generated in response to
stimulation with alloantigens (Chan et al., 2002).We showed previous-
ly that polyclonal and allogeneic stimulation results in upregulation of
CD30 on memory T-cells and an INF-γ-dependent release of sCD30
from these cells (Velasquez et al., 2013). Although a biological function
of sCD30 has not been established in vivo, sCD30 has greater afﬁnity for
CD30-ligand in vitro as compared to CD30 and is potentially capable of
blocking CD30, CD30-ligand interactions (Hargreaves and Al-
Shamkhani, 2002), reducing the availability of CD30-ligand on lympho-
cytes or decreasing the ability of regulatory T-cells to inhibit graft-reac-
tive T-cells (Tarkowski, 2003). Neutralization of IFN-γ resulted in
abrogation of sCD30 release from memory T-cells in vitro (Velasquez
et al., 2013). High production of IFN-γ by alloreactive anti-donor effec-
tor memory T-cells in patients awaiting kidney transplantation has
been associated with early acute rejection of kidney transplants
(Heeger et al., 1999). The presence of a low-level or declining memory
T-cell responsemight serve as an explanationwhy, despite the presence
of DSA, many patients possess low sCD30 levels. Routinely applied im-
munosuppression appears to be able to control such low-level T-cell-
mediated antibody responses.
In sCD30 and DSA positive patients, some 40% of transplanted kid-
neys failed within 3 years. This rate is unacceptable. Allocation of HLA
well-matched donor kidneys to these truly “high risk” patients may be
an effective approach to minimize graft loss. It was shown in previous
studies that deleterious sCD30 as well as HLA antibody effects can suc-
cessfully be compensated by good HLA matching (Susal et al., 2003;
Susal et al., 2009). Special desensitization and immunosuppression pro-
grams may be suitable alternatives. Because of the side effects associat-
ed with such treatment, many centers do not perform transplants fromlive donors if DSA are present. Our data suggest that transplantations
can be safely performed in DSA positive patients if the pretransplant
sCD30 level is low. However, before such policy can be generally imple-
mented, further studies are required that conﬁrm the present ﬁndings.
Limitations of the present study are its retrospective nature and the
lacking demonstration of the mechanism how DSA exert their harmful
effect in dependence of a preactivated immune system. Switch of B
cells under T-cell support to long-lived plasma cells, which produce
harmful antibody isotypes, and a potential predisposition of certain pa-
tients to the simultaneous production of sCD30 and persistent DSA are
issues that remain to be addressed in future studies. Strengths of the
study are the robustness of the presented ﬁndings, which due to the
strong impact on graft outcome should be readily reproducible by
other research groups, and their technically uncomplicated potential
applicability for clinical routine.
In conclusion, our data indicate that the presence of pretransplant
DSA is associated with a high rate of graft rejection only if patients con-
comitantly have high levels of pretransplant sCD30 which reﬂect a
preactivated immune response. For practical purposes, it appears that
only patients positive for both DSA and sCD30 require special therapeu-
tic and organizationalmeasures, such as the elimination of DSA from the
patient's circulation, potent immunosuppression, good HLA matching
and intense posttransplant monitoring (Morath et al., 2010; Susal et
al., 2003; Susal et al., 2009). According to this analysis, the majority of
pretransplant DSA positive patients exhibit low sCD30 levels and can
be expected to enjoy good graft survival without special provisions.
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